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3Abstract
Aims: To quantify the determinants of primary PCI performance in England and
Wales between 2004 and 2007.
Methods and results: All 8,653 primary PCI cases admitted to acute hospitals in
England and Wales as recorded in the Myocardial Ischaemia National Audit Project
(MINAP) 2004–7. We studied the impact of the volume of primary PCI cases
(hospital volume) on DTB times and the proportion of patients treated with primary
PCI (hospital proportion) on 30-day mortality and employed regression analysis to
identify reasons for DTB time variations with a multilevel component to express
hospital variation. The proportion of patients receiving pPCI increased from 5% in
2004 to 20% in 2007. Median DTB times reduced from 84 minutes in 2004 to 61
minutes in 2007. Median DTB times decreased as the number of pPCI procedures
increased. The 30-day all cause mortality rate, 95% CI for hospitals that performed
pPCI for less than 25% of STEMI patients was significantly higher than those that
performed pPCI for greater than 75% (5.0%, 3.9% to 6.1% versus 2.7%, 2.0% to
3.5%). Time-of-day, year of admission, sex and diabetes significantly influenced DTB
times. Hospital variation was evident by a hospital-level DTB time standard deviation
of 12 minutes.
Conclusions: There was large variation in DTB times between the best and worst
performing hospitals. Although patient-related factors impact upon DTB times,
volume and proportion of patients undergoing primary PCI significantly influence
4delay and early mortality - hospitals with the highest proportion of primary PCI had
the lowest mortality.
Key words: Primary PCI; STEMI; door-to-balloon time; mortality; hospital volume;
hospital proportion.
5Introduction
The benefits of primary PCI diminish if there are delays to revascularisation of the
infarct-related artery 1-4; longer revascularisation times are associated with increased
in-hospital mortality 5-7. Hospital-level influences account for up to a third of the
‘total ischaemic time’ and incorporate many factors, including the availability of a
skilled catheterisation laboratory team (specialist centre effect); the number of
patients treated (hospital volume effect) and patient–level factors 7-15.
Earlier studies revealed that lower volume primary PCI centers conferred elevated
mortality 9,11,15,17. Recently, however, this has been debated 12,17 with evidence from
the National Registry of Myocardial Infarction to suggest that a greater level of
hospital ‘specialisation’ was associated with reduced in-hospital mortality 12. Indeed,
integrated systems of care that redirect ST-elevation myocardial infarction (STEMI)
patients to higher volume, higher ‘specialisation’ interventional centres (where greater
proportions of STEMI cases undergo primary PCI) may offer improved outcomes
beyond the length of the hospital admission. Currently such ‘Heart Attack Centers’ do
not exist in England and Wales although there is a strategy to provide a national
primary PCI service for STEMI, by 2012 18. This study therefore aimed to quantify
the determinants of primary PCI performance for STEMI patients in England and
Wales during the period 2004–2007, and to investigate the impact of hospital
reperfusion strategies on primary PCI performance.
6Methods
Study design
The analyses were based on data from the Myocardial Ischaemia National Audit
Project (MINAP) whose national database was established in 1999 to examine the
quality of management of acute myocardial infarction in England and Wales and to
meet the audit requirements of the National Service Framework for coronary heart
disease19. MINAP has been long established as a vehicle for evaluating service
provision especially regarding call-to-needle (CTN) and door-to-needle (DTN) times
for thrombolysis 20-22. This clinical database collects patient data from all acute
hospitals in England and Wales 23-25.
Data for patients admitted with an acute coronary syndrome (ACS) are collected
prospectively at each acute hospital by a secure electronic system, developed by the
Central Cardiac Audit Database (CCAD), electronically encrypted and transferred on-
line to a central database 26. CCAD is part of the National Clinical Audit Support
Programme (NCASP) 27 which is part of the National Health Service (NHS)
Information Centre for Health and Social Care 28. MINAP is overseen by a multi
professional steering group representing the stakeholders and is based at the National
Institute for Clinical Outcomes Research (NICOR) at University College London 23.
Each patient entry offers details of the patient journey, including the method and
timing of admission, in-patient investigations, treatment, and date of all cause death
7(from linkage to the UK Statistics Authority using a unique NHS number). Data entry
is subject to routine on-line error checking. There is a mandatory annual data
validation exercise for each hospital 20.
Analogous to the annual national audit of thrombolysis times20, primary PCI
performance is evaluated using times to reperfusion. In 2009, the call to balloon
(CTB) time was adopted by the NHS Information Centre for Health and Social Care
as a new indicator of quality improvement for acute care 29. Our study specifically
focuses on hospital performance and therefore analyses are based upon the door to
balloon time (DTB), akin to the door-to-needle time for thrombolysis. The DTB time
is a hospital-based performance indicator30,31 and is defined as the difference between
the time of arrival of the ambulance to the first hospital and the time of first balloon
inflation (the accident and emergency time is taken if the patient self presents to
hospital).
Cohort description
The MINAP cohort comprised 324,083 independent ACS events admitted to acute
hospitals in England and Wales between 1st January 2004 and 31st December 2007. Of
these, there were 71,995 patients with an initial diagnosis of STEMI.
Statistical methods
The population was described by unadjusted numbers, percentages with 95%
confidence intervals with respect to discrete data, and by medians and interquartile
range or mean ±1.96 SD for continuous variables. Pearson’s chi-squared test was used
to determine whether there was a significant difference between the expected
8frequencies and the observed frequencies in one or more categories. The Mann–
Whitney U test was used to assess whether two independent samples arose from the
same distribution. The time of admission was divided into ‘day’ and ‘night’ with day
defined as 08:00 until 20:00. Temporal data were smoothed using a LOESS algorithm
32.
To account for variations at the hospital level, a linear mixed-effects regression model
was used to model the relationship between DTB times and age, year of admission,
time-of-arrival (day or night), diabetic status, hospital proportion of cases, and Index
of Multiple Deprivation (IMD) score. The IMD score combines information on
income, employment, health deprivation and disability, education skills and training,
housing, geographical access to services, and living environment for areas containing
a minimum of 1,000 people and 400 households. The primary PCI proportion per
hospital was defined as the number of patients with an admission diagnosis of STEMI
who underwent primary PCI divided by the global number of cases with an admission
diagnosis of STEMI for that hospital. The selection of covariates for the model was
based upon those that were clinically and statistically significant. Hospitals with less
than 10 primary PCI cases were excluded 29. Of the STEMI cohort, 5.6% had missing
data for 30-day mortality. The DTB times were 85% complete.
9Results
There were 8,653 (12%) patients who underwent primary PCI. The mean age for the
primary PCI cohort was 62.9 years (95% confidence interval: 62.8 years to 63.1
years), 74.1% were male and 13.9% had diabetes. The mean (95% confidence
interval) systolic BP and heart rate on admission was 136.7 mmHg (79.8 mmHg to
193.6 mmHg) and 77.0 bpm (37.4 bpm to 116.6 bpm) respectively. The baseline
characteristics for the cohort are presented by year in Table 1.
30-day mortality
The unadjusted all-cause 30-day mortality for primary PCI was 4.1% (95%
confidence interval: 3.7% to 4.6%). Primary PCI 30-day mortality rates fell, reaching
3.3% (95% confidence interval: 2.7% to 4.1%) in 2007 from 5.3% (95% confidence
interval: 3.6% to 7.0%) in 2004.
Year and time of admission
The total number of treated STEMI cases fell from 19,757 in 2004 to 15,573 in 2007.
The rate of introduction of the primary PCI service is presented in Figure 1. In 2005
5% of STEMI cases were treated using primary PCI (n = 915) compared with 9% (n =
1,744) in 2005, 16% (n = 2,853) in 2006, and 20% (n = 3,141) in 2007 (Chi-squared
for trend = 2348.59, df = 3, P <0.001). Over the 4 years the total rates of reperfusion
for STEMI (thrombolysis and primary PCI) remained constant at approximately 70%.
Two thirds of patients who underwent primary PCI (66%) were treated between 08:00
and 20:00.
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Hospital volume and proportion effect
Figure 2 shows that there was a significant difference in the 30-day all cause mortality
rate, 95% CI for those hospitals that performed primary PCI for fewer than 25% of
STEMI patients compared to more than 75% (5.0%, 3.9% to 6.1% versus 2.7%, 2.0%
to 3.5%). There was no significant relationship between the number of primary PCI
cases undertaken (hospital volume) and 30-day all cause mortality. However, higher
volume centres had shorter DTB times (Figure 3).
Reperfusion times
The median DTB time for males was 8 minutes shorter than for females (Table 2).
The median DTB time for patients with diabetes was 71 minutes (interquartile range
66 minutes), whereas for patients without diabetes the median DTB time was 67
minutes (interquartile range 58 minutes).
Figure 4 demonstrates significant diurnal variation in DTB times over 24 hours – with
evidence for nocturnal peaks and daytime troughs. The longest DTB times occurred at
approximately 08:00, whilst the shorter DTB times occurred between 09:00 and
20:00.
There was a year-on-year decrease in the DTB times (Figure 5). In 2004 the median
DTB time was 84 minutes and 56% of patients were reperfused within 90 minutes. By
2007 the median time reduced by 23 minutes to 61 minutes and a further 20% (total
76%) of patients were reperfused within 90 minutes.
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Modelling the DTB time
The DTB times by night were 11 minutes longer than those by day (Table 3). Females
and those with diabetes had DTB times 3.5 minutes greater than males and patients
without diabetes. Each year an improvement in DTB times was observed. Hospitals
that performed primary PCI on greater than 75% of STEMIs had DTB times 30
minutes shorter than hospitals which performed PCI on less than 75% of STEMIs: the
hospital-proportion effect.
Younger patients had shorter DTB times than older patients. For example, a 40 year
patient would, on average have a DTB time 4 minutes shorter than an 80 year old
patient. Patients with higher IMD scores (more deprived) are predicted to have longer
DTB times than those with lower IMD scores. The hospital effect for DTB times
(after accounting for the hospital proportion effect.) was predicted to be 51 minutes
between the best and worst performing hospitals. The residual variation in DTB times
was greater at the patient-level (SD = 32.7 minutes) than at the hospital-level (SD =
12.1 minutes).
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Discussion
This study identifies several important details relating to variations in DTB times and
early mortality: namely the time-of-day effect; the hospital effect, the hospital volume
effect and the hospital-proportion effect, and are in keeping with findings from other
registries 9,10,12,14,16,33-35. In particular, it readily shows that 1) high volume centres
have lower DTB times, 2) there is a statistically significant difference in mortality
rates between those hospitals that perform primary PCI on over 75% of STEMI
patients compared with less that 25% (2.7% versus 5.0% respectively), and that 3)
high volume centres do not have lower mortality rates than low volume centres. This
study therefore demonstrates that of the analyses, it is the proportion rather than
volume of primary PCIs undertaken that is more relevant to improved primary PCI
performance at the hospital level 17.
The multilevel analysis splits the variation in DTB times into components associated
with the patient and with the hospital. Increasing age, female sex and diabetes are
associated with small but statistically significant longer DTB times. In contrast, the
individual hospital effects are much larger – they clearly demonstrate that it does
matter at which hospital a patient is admitted – there is a statistically and clinically
significant delay at some hospitals, the best being almost an hour faster than the
slowest. The service in many hospitals in England and Wales, however, is evolving:
DTB times and 30-day mortality rates overall have decreased as the service has
evolved so that the variation between hospitals may be due solely to the different
degrees with which primary PCI has become an established treatment option.
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We report a significant year-on-year reduction in the number of STEMI cases and a
trend towards reduced annual 30-day mortality rates from primary PCI. The reduction
in rates of STEMI is consistent with previously reported registries 36. Patient
characteristics including cardiogenic shock, diabetes, previous myocardial infarction,
angina, chronic renal failure and hypertension (see Table 1) did not vary considerably
between 2004 and 2007 and are therefore unlikely to explain the reduction in
mortality rates. Instead, increased 30-day mortality was associated with hospitals that
performed primary PCI on a low proportion of STEMI patients. This study builds on
the notion that hospitals with high levels of ‘specialisation’ are associated with lower
mortality rates 12 to show that the hospital proportion effect extends beyond the length
of the hospital admission to 30 days. It is likely that a statistically significant
reduction in mortality was not evident between 2004 and 2007 because there was little
change in the proportion of hospitals performing primary PCI on less than 50% of
STEMI cases. We speculate that an increase in the numbers of centres performing
primary PCI on over 75% of STEMI cases would offer greater reductions in 30-day
mortality rates. Indeed, analysis of the National Registry of Myocardial Infarction-4
has revealed that a 36% relative risk reduction in in-hospital mortality was evident for
centres performing primary PCI on over 88.5% of STEMI cases compared to those
performing it on less than 34.0% 12.
Those hospitals that perform primary PCI on over 75% of STEMIs are very likely to
offer a 24-hour primary PCI service. When a 24-hour primary PCI service is
provided, it is apparent that DTB times are longer at night - consistent with the
healthcare team being called in for the procedure – at the time of analysis there were
no primary PCI centres in England and Wales which had a policy whereby the
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primary PCI team and first operator were resident in the hospital. Furthermore, the
increase in DTB times between 07:00 and 09:00 is likely to be due to a decision to
wait until the primary PCI team was available 8. With evidence to suggest that delays
to reperfusion are associated with higher mortality rates 1,5,7, this might be
investigated in more detail at specific hospitals and raises the issue of the decision to
thrombolyse should primary PCI only be available after a delay 6,37,38. An alternative
model of care would be large volume, high proportion ‘heart attack centres’ with 1) a
24 hour primary PCI service, 2) dedicated primary PCI catheter labs, and 3) a primary
PCI team (including the first operator) resident in the hospital.
Whilst there is evidence to suggest that two-thirds of the delay to revascularisation
occurs before first medical contact (patient delay) 39, there remains a substantial
opportunity for improvement at the hospital level: for example, over the 4 years
studied, there was no appreciable decrease in the number of patients with STEMI not
reperfused. This is surprising when primary PCI has fewer contra-indications than
thrombolysis 40. We clearly identify hospital characteristics (high volume) which are
associated with reduced DTB times and a model of delivery of care (high proportion)
associated with reduced early 30-day mortality. Consequently, this research brings to
light the necessity for consideration of high throughput "Heart Attack Centres" and
provides additional evidence to support the need for strategic networks of care 46.
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Limitations
MINAP does not collect data on all ACS patients in England and Wales and it is
possible that patients entered into the MINAP database differ from those not recorded.
We noted that the recording of DTB times was 85% complete and the resulting bias
due to missing data could potentially be large 47. Between 2004 and 2007, the
emergency management of STEMI in England and Wales differed from that of other
countries - the primary PCI rate in other health care systems at a similar period in time
was higher 40,48,49. Nonetheless England and Wales compared favorably with data
from North America, where in 2004 the median DTB time was reported as 100.4 ± 23
minutes 50. The modelling of DTB times was limited to 9 key variables and this may
have not considered other determinants of DTB times. Hospital performance may
have changed recently as this study only considers data to the end of 2007 20. Finally,
this research reveals important associations but cannot prove cause and effect.
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Conclusions
Several primary PCI hospital process-related factors have been identified: namely the
time-of-day effect; the hospital effect and the hospital-proportion effect. These are
central to the development and evaluation of a national primary PCI service. In
addition to patient related factors that impact upon DTB times, volume and proportion
of patients treated with primary PCI influence delay and early mortality. This paper
provides evidence to support the concept of ‘Heart Attack Centres’ where high
throughput primary PCI offers improved patient care.
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Table 1. Baseline characteristics for the primary PCI cohort.
2004 2005 2006 2007
Number of primary PCI cases 915 1744 2853 3141
Demographics
Mean (SD) age, years 62.2 (12.8) 62.5 (12.8) 63.1 (13.5) 63.2 (12.9)
Male sex (%) 674 (73.7) 1316 (75.5) 2089 (73.2) 2304 (73.3)
Median (IQR) IMD score* 25.8 (28.3)) 23.5 (25.8) 21.1 (25.1) 20.2 (25.3)
Cardiovascular risk factors
Previous myocardial infarction (%) 131 (14.3) 212 (12.2) 354 (12.4) 404 (12.9)
Previous angina (%) 130 (14.2) 249 (14.3) 407 (14.3) 401 (12.8)
Hypertension (%) 355 (38.8) 683 (39.2) 1153 (40.4) 1154 (36.7)
Diabetes (%) 116 (12.7) 221 (12.7) 371 (13.0) 402 (12.7)
Current smoker (%) 419 (45.8) 693 (39.7) 1040 (36.4) 1161 (37.0)
Chronic renal failure (%) 20 (2.2) 25 (1.4) 46 (1.6) 56 (1.8)
Haemodynamic characteristics
Mean (SD) systolic BP, mmHg 136.2 (28.7) 137.1 (28.4) 137.1 (29.8) 136.2 (29.6)
Mean (SD) heart rate, bpm 75.7 (21.2) 76.8 (19.7) 77.3 (20.3) 77.2 (20.1)
Cardiogenic shock (%) 22 (2.4) 37 (2.1) 81 (2.8) 102 (3.2)
Reperfusion times
Median (IQR) CTB time, minutes 133 (85) 128 (61) 117 (54) 112 (49)
Median (IQR) DTB time, minutes 84 (60) 77 (66) 65 (61) 61 (63)
Treatments
Aspirin on admission (%) 728 (79.6) 1457 (83.5) 2311 (81.0) 2785 (88.7_
Aspirin on discharge (%) 736 (80.4) 1248 (71.6) 2238 (78.4) 2679 (85.3)
Clopidogrel on discharge (%) 81 (8.8) 634 (36.3) 1737 (60.8) 2253 (71.2)
Statin on discharge (%) 731 (79.9) 1262 (72.4) 2219 (77.8) 2674 (85.1)
β blocker on discharge (%) 640 (69.9) 1096 (62.8) 1918 (67.2) 2341 (74.5) 
ACE inhibitor on discharge (%) 682 (74.5) 1176 (67.4) 2045 (71.7) 2489 (79.2)
*Index of Multiple Deprivation, higher scores signify greater deprivation.
CTB: call to balloon; DTB: door to balloon
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Figure 1. Primary PCI and thrombolysis rates adjusted for STEMI admission rate.
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Figure 2: 30-day mortality rate by proportion of STEMI cases treated by primary
PCI.
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Figure 3: Median door to balloon time (minutes) by hospital volume and proportion
of primary PCI cases.
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Table 2: Median and interquartile range (IQR) of DTB times by sex and diabetic
status.
Characteristic Median (IQR) DTB time,minutes
Level of significance
Sex
Male 65 (57)
P<0.001Female 73 (62)
Diabetes
Yes 71 (66)
P = 0.03No 67 (58)
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Figure 4: Diurnal variation in DTB times.
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Figure 5: Box-plot of DTB times by year of admission.
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Table 3: Modelling of DTB times to show the impact of confounding variables.
Estimate (95% confidence interval),
minutes
Fixed effects:
Intercept^ 85.2 (79.9 to 90.4)
Arrival at night 11.5 (9.3 to 13.7)
Year 2005 -6.0 (-9.3 to -2.8)
Year 2006 -12.0 (-15.1 to -8.9)
Year 2007 -18.4 (-22.1 to -14.7)
Female 3.5 (1.1 to 5.8)
Diabetes 3.9 (1.0 to 6.8)
Age (by 1 year) 0.1 (0 to 0.2)
Hospital proportion >75% -29.9 (-42 2 to -17.7)
IMD score* 0.1 (0.1 to 0.2)
Random effects:
Hospital standard deviation 12.1 (9.2 to 16.0)
Patient level standard deviation 32.7 (32.0 to 33.4)
^The reference group time is for a 63 year-old male without diabetes admitted in 2004
to a hospital with a primary PCI rate of less than 75% and living in area with an IMD
score of 20.
*Index of Multiple Deprivation.
25
Reference List
1. Rathore SS, Curtis JP, Chen J, Wang Y, Nallamothu BK, Epstein AJ, Krumholz
HM, for the National Cardiovascular Data Registry. Association of door-to-
balloon time and mortality in patients admitted to hospital with ST elevation
myocardial infarction: national cohort study. BMJ 2009;338(may19_1):b1807.
2. Terkelsen CJ, Christiansen EH, Sorensen JT, Kristensen SD, Lassen JF,
Thuesen L, Andersen HR, Vach W, Nielsen TT. Primary PCI as the preferred
reperfusion therapy in STEMI: it is a matter of time. Heart 2009;95(5):362-369.
3. Nallamothu B, Fox KA, Kennelly BM, Van de WF, Gore JM, Steg PG, Granger
CB, Dabbous OH, Kline-Rogers E, Eagle KA. Relationship of treatment delays
and mortality in patients undergoing fibrinolysis and primary percutaneous
coronary intervention. The Global Registry of Acute Coronary Events. Heart
2007.
4. De LG, Suryapranata H, Zijlstra F, van 't Hof AW, Hoorntje JC, Gosselink AT,
Dambrink JH, de Boer MJ. Symptom-onset-to-balloon time and mortality in
patients with acute myocardial infarction treated by primary angioplasty. J Am
Coll Cardiol 2003;42(6):991-997.
5. McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, Peterson
ED, Blaney M, Frederick PD, Krumholz HM. Effect of door-to-balloon time on
mortality in patients with ST-segment elevation myocardial infarction. J Am
Coll Cardiol 2006;47(11):2180-2186.
6. Tarantini G, Razzolini R, Napodano M, Bilato C, Ramondo A, Iliceto S.
Acceptable reperfusion delay to prefer primary angioplasty over fibrin-specific
thrombolytic therapy is affected (mainly) by the patient's mortality risk: 1 h does
not fit all. Eur Heart J 2010;31(6):676-683.
7. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ,
Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Jr., Antman EM,
Cannon CP, Gibson CM. Hospital Delays in Reperfusion for ST-Elevation
Myocardial Infarction: Implications When Selecting a Reperfusion Strategy.
Circulation 2006;114(19):2019-2025.
8. Huber K, Goldstein P, Danchin N, Fox KAA. Network models for large cities:
the European experience. Heart 2010;96(2):164-169.
9. Magid DJ, Calonge BN, Rumsfeld JS, Canto JG, Frederick PD, Every NR,
Barron HV, for the National Registry of Myocardial Infarction. Relation
Between Hospital Primary Angioplasty Volume and Mortality for Patients With
Acute MI Treated With Primary Angioplasty vs Thrombolytic Therapy. JAMA:
The Journal Of The American Medical Association 2000;284(24):3131-3138.
10. Canto JG, Every NR, Magid DJ, Rogers WJ, Malmgren JA, Frederick PD,
French WJ, Tiefenbrunn AJ, Misra VK, Kiefe CI, Barron HV. The volume of
primary angioplasty procedures and survival after acute myocardial infarction.
26
National Registry of Myocardial Infarction 2 Investigators. N Engl J Med
2000;342(21):1573-1580.
11. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie
P, Donohue B, Chelliah N, Timmis GC, . A comparison of immediate
angioplasty with thrombolytic therapy for acute myocardial infarction. The
Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med
1993;328(10):673-679.
12. Nallamothu BK, Wang Y, Magid DJ, McNamara RL, Herrin J, Bradley EH,
Bates ER, Pollack CV, Jr., Krumholz HM. Relation between hospital
specialization with primary percutaneous coronary intervention and clinical
outcomes in ST-segment elevation myocardial infarction: National Registry of
Myocardial Infarction-4 analysis. Circulation 2006;113(2):222-229.
13. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary
angioplasty versus immediate thrombolysis in acute myocardial infarction: a
meta-analysis. Circulation 2003;108(15):1809-1814.
14. Spaulding C, Morice MC, Lancelin B, El HS, Lepage E, Bataille S, Tresca JP,
Mouranche X, Fosse S, Monchi M, de VN. Is the volume-outcome relation still
an issue in the era of PCI with systematic stenting? Results of the greater Paris
area PCI registry. Eur Heart J 2006;27(9):1054-1060.
15. Terkelsen CJ, Lassen JF. Treatment delays in ST elevation myocardial
infarction. BMJ 2008;336(7641):401-402.
16. Tsuchihashi M, Tsutsui H, Tada H, Shihara M, Takeshita A, Kono S. Volume-
outcome relation for hospitals performing angioplasty for acute myocardial
infarction: results from the Nationwide Japanese Registry. Circ J
2004;68(10):887-891.
17. Kumbhani DJ, Cannon CP, Fonarow GC, Liang L, Askari AT, Peacock WF,
Peterson ED, Bhatt DL, for the Get With the Guidelines Steering Committee
and Investigators. Association of Hospital Primary Angioplasty Volume in ST-
Segment Elevation Myocardial Infarction With Quality and Outcomes. JAMA:
The Journal Of The American Medical Association 2009;302(20):2207-2213.
18. DH Vascular Programme Team. Treatment of Heart Attack National Guidance.
Final Report of the National Infarct Angioplasty Project (NIAP). Department of
Health. 2008.
19. Department of Health (2000) National Service Framework for coronary Heart
Disease. The Stationary Office, London.
20. How the NHS manages heart attacks. Eigth public report 2009t. National
Institute for Clinical Outcomes Research, London 2009.
21. Birkhead JS, Walker L, Pearson M, Weston C, Cunningham AD, Rickards AF.
Improving care for patients with acute coronary syndromes: initial results from
the National Audit of Myocardial Infarction Project (MINAP). Heart
2004;90(9):1004-1009.
27
22. Birkhead JS. Trends in the provision of thrombolytic treatment between 1993
and 1997. Myocardial Infarction Audit Group. Heart 1999;82(4):438-442.
23. http://www.rcplondon.ac.uk/college/ceeu/ceeu_ami_home.htm. Accessed
February 2010.
24. Birkhead J, Walker L. National audit of myocardial infarction (MINAP): a
project in evolution. Hosp Med 2004;65(8):452-453.
25. Birkhead JS. Responding to the requirements of the national service framework
for coronary disease: a core data set for myocardial infarction. Heart
2000;84(2):116-117.
26. Rickards A, Cunningham D. From quantity to quality: the central cardiac audit
database project. Heart 1999;82(90002):18ii-22.
27. http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp.
Accessed February 2010. 2010.
28. http://www.ic.nhs.uk/. Accessed February 2010. 2010.
29. https://mqi.ic.nhs.uk/IndicatorDefaultView.aspx?ref=1.01.01. Accessed
September 2009. 2009.
30. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM,
Ho PM, Kosiborod MN, Masoudi FA, Nallamothu BK. ACC/AHA 2008
performance measures for adults with ST-elevation and non-ST-elevation
myocardial infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Performance Measures
(Writing Committee to Develop Performance Measures for ST-Elevation and
Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the
American Academy of Family Physicians and American College of Emergency
Physicians Endorsed by the American Association of Cardiovascular and
Pulmonary Rehabilitation, Society for Cardiovascular Angiography and
Interventions, and Society of Hospital Medicine. J Am Coll Cardiol
2008;52(24):2046-2099.
31. Tu JV, Khalid L, Donovan LR, Ko DT. Indicators of quality of care for patients
with acute myocardial infarction. CMAJ 2008;179(9):909-915.
32. de Boor C. A practical guide to splines. Springer-Verlag. 1978.
33. Magid DJ, Wang Y, Herrin J, McNamara RL, Bradley EH, Curtis JP, Pollack
CV, Jr., French WJ, Blaney ME, Krumholz HM. Relationship Between Time of
Day, Day of Week, Timeliness of Reperfusion, and In-Hospital Mortality for
Patients With Acute ST-Segment Elevation Myocardial Infarction. JAMA: The
Journal Of The American Medical Association 2005;294(7):803-812.
34. Cubeddu RJ, Cruz-Gonzalez I, Kiernan TJ, Truong QA, Rosenfield K, Leinbach
RC, Cadigan ME, Pomerantsev EV, Palacios IF. ST-elevation myocardial
infarction mortality in a major academic center "on-" versus "off-" hours. J
Invasive Cardiol 2009;21(10):518-523.
28
35. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary
percutaneous coronary intervention. N Engl J Med 2007;357(16):1631-1638.
36. Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, Pollack
Jr CV, Gore JM, Chandra-Strobos N, Peterson ED, French WJ. Trends in
presenting characteristics and hospital mortality among patients with ST
elevation and non-ST elevation myocardial infarction in the National Registry of
Myocardial Infarction from 1990 to 2006. American Heart Journal
2008;156(6):1026-1034.
37. Van de WF, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V,
Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M,
Verheugt F, Weidinger F, Weis M, Vahanian A, Camm J, De CR, Dean V,
Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD,
McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL,
Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt
O, Danchin N, Di MC, Dudek D, Gulba D, Halvorsen S, Kaufmann P,
Kornowski R, Lip GY, Rutten F. Management of acute myocardial infarction in
patients presenting with persistent ST-segment elevation: the Task Force on the
Management of ST-Segment Elevation Acute Myocardial Infarction of the
European Society of Cardiology. Eur Heart J 2008;29(23):2909-2945.
38. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus
fibrinolytic therapy in acute myocardial infarction: is timing (almost)
everything? Am J Cardiol 2003;92(7):824-826.
39. Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG, Van de Werf F,
Lopez-Sendon J, Goodman SG, Quill A, Fox KAA, for the Global Registry of
Acute Coronary Events (GRACE) Investigators. Trends in acute reperfusion
therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we
are getting better but we have got a long way to go. European Heart Journal
2008;29(5):609-617.
40. Grines CL, Serruys P, O'Neill WW. Fibrinolytic therapy: is it a treatment of the
past? Circulation 2003;107(20):2538-2542.
41. Fox KA, Huber K. A European perspective on improving acute systems of care
in STEMI: we know what to do, but how can we do it? Nat Clin Pract
Cardiovasc Med 2008;5(11):708-714.
42. Knot J, Widimsky P, Wijns W, Stenestrand U, Kristensen SD, Van' TH,
Weidinger F, Janzon M, Norgaard BL, Soerensen JT, van de WH, Thygesen K,
Bergsten PA, Digerfeldt C, Potgieter A, Tomer N, Fajadet J. How to set up an
effective national primary angioplasty network: lessons learned from five
European countries. EuroIntervention 2009;5(3):299, 301-299, 309.
43. Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, Lips
DL, Madison JD, Menssen KM, Mooney MR, Newell MC, Pedersen WR,
Poulose AK, Traverse JH, Unger BT, Wang YL, Larson DM. A Regional
System to Provide Timely Access to Percutaneous Coronary Intervention for
ST-Elevation Myocardial Infarction. Circulation 2007;116(7):721-728.
29
44. Holmes DR, Jr., Bell MR, Gersh BJ, Rihal CS, Haro LH, Bjerke CM, Lennon
RJ, Lim CC, Ting HH. Systems of care to improve timeliness of reperfusion
therapy for ST-segment elevation myocardial infarction during off hours: the
Mayo Clinic STEMI protocol. JACC Cardiovasc Interv 2008;1(1):88-96.
45. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L,
Andrikopoulos G, Baz JA, Betriu A, Claeys M, Danchin N, Djambazov S, Erne
P, Hartikainen J, Huber K, Kala P, Klin-ìeva M, Kristensen SD, Ludman P,
Ferre JM, Merkely B, Mili-ìi-ç D, Morais J, No-ì M, Opolski G, Ostoji-ç M,
Radovanovi-ì D, de Servi S, Stenestrand U, Studen-ìan M, Tubaro M, Vasiljevi-
ç Z, Weidinger F, Witkowski A, Zeymer U. Reperfusion therapy for ST
elevation acute myocardial infarction in Europe: description of the current
situation in 30 countries. European Heart Journal 2010;31(8):943-957.
46. McCullag P, Nelder JA. Generalized Linear Models, 2nd ed. London: Chapman
& Hall. 1989.
47. Cattle BA, Greenwood DC, Gale CP, West RM. Ups and downs of balloon
times. BMJ 2009;338(jun15_1):b2424.
48. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, Gitt A,
Hasdai D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Behar S, on behalf
of the Euro Heart Survey Investigators. The second Euro Heart Survey on acute
coronary syndromes: characteristics, treatment, and outcome of patients with
ACS in Europe and the Mediterranean Basin in 2004. European Heart Journal
2006;27(19):2285-2293.
49. Widimsky P, Wijns W, Fajadet J, de BM, Knot J, Aaberge L, Andrikopoulos G,
Baz JA, Betriu A, Claeys M, Danchin N, Djambazov S, Erne P, Hartikainen J,
Huber K, Kala P, Klinceva M, Kristensen SD, Ludman P, Ferre JM, Merkely B,
Milicic D, Morais J, Noc M, Opolski G, Ostojic M, Radovanovic D, De SS,
Stenestrand U, Studencan M, Tubaro M, Vasiljevic Z, Weidinger F, Witkowski
A, Zeymer U. Reperfusion therapy for ST elevation acute myocardial infarction
in Europe: description of the current situation in 30 countries. Eur Heart J
2010;31(8):943-957.
50. Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis
SA, Curtis JP, Nallamothu BK, Magid DJ, McNamara RL, Parkosewich J, Loeb
JM, Krumholz HM. Strategies for reducing the door-to-balloon time in acute
myocardial infarction. N Engl J Med 2006;355(22):2308-2320.
